Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Published byMelvin Lamb Modified over 5 years ago

Similar presentations

Presentation on theme: "Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated."— Presentation transcript:

1 Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Clinical details of patient 1 (not including immunologic studies) were reported previously (30). After IFNβ monotherapy, patient 1 subsequently experienced 8+ years of disease-free survival. Three patients who received intralesional IFN injections as part of their MCC treatment who had specimens available from before and after IFN treatment are shown. A significant increase in MHC-I expression was observed on tumor cells after treatment (P = 0.04; paired t test). Kelly G. Paulson et al. Cancer Immunol Res 2014;2: ©2014 by American Association for Cancer Research

Download ppt "Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated."

Similar presentations

Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.
Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.

Depletion of T cells, in particular CD8+ T cells, significantly abrogates HEV neogenesis in tumors. Depletion of T cells, in particular CD8+ T cells, significantly.
Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.
B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
IL32 prompts cell activation and cancer-related pathways.

IL32 prompts cell activation and cancer-related pathways.
Quantification of MHC-I, β2m, and T-cell subsets.

Quantification of MHC-I, β2m, and T-cell subsets.
CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.
Exosome-mediated inhibition of T cells is reversible.

Exosome-mediated inhibition of T cells is reversible.
Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.
L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.
Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.
Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.

Geographic colocalization of PD-L1+ tumor cells with infiltrating immune cells in MCC. The predominant pattern of tumor cell PD-L1 expression is at the.
IL32 is highly expressed in mycosis fungoides lesional skin.

IL32 is highly expressed in mycosis fungoides lesional skin.
Treatment with R848 and anti-CD200R leads to changes in the composition of intratumor myeloid cells. Treatment with R848 and anti-CD200R leads to changes.

Treatment with R848 and anti-CD200R leads to changes in the composition of intratumor myeloid cells. Treatment with R848 and anti-CD200R leads to changes.
coTCRcys-transduced T cells control tumor growth in vivo.

coTCRcys-transduced T cells control tumor growth in vivo.

Similar presentations

Ads by Google